Bilthoven Biologicals, is  a bio-engineering and pharmaceutical company  which remains at the forefront of vaccine production.  Acquired from the Netherlands Government in 2012, the acquisition ensures access to technology and expertise for making the IPV (Inactivated Polio Vaccine, Salk) earlier possessed by only three other vaccine manufacturers.

Bilthoven Biologicals is spread over 40 acres with an installed manufacturing capacity of over 20 million doses of vaccines annually. The production facilities are state-of-art and fully compliant with cGMP and biopharmaceutical requirements.

Bilthoven Biologicals produce two semi-exclusive products: the inactivated polio vaccine and the Bacillus Calmette-Guérin (BCG) vaccine for bladder cancer treatment. This acquisition enhances Serum Institute’s offerings in the pediatric vaccine segment and with this they hope to make a significant contribution to the eradication of Polio from the World.  Bilthoven Biologicals also provides an important manufacturing base in Europe with access to strategic European markets for Serum Institute.

Visit Bilthoven Biologicals Website